Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness

V Lejon; J Robays; FX N'Siesi; D Mumba; A Hoogstoel; S Bisser; H Reiber; M Boelaert; P Büscher

doi:10.1128/CVI.00103-07

Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness

V Lejon, J Robays, FX N'Siesi, D Mumba, A Hoogstoel, S Bisser, H Reiber, M Boelaert, P Büscher

Research output: Contribution to journal › A1: Web of Science-article › peer-review

Original language	English
Journal	Clinical and Vaccine Immunology
Volume	14
Issue number	6
Pages (from-to)	732-737
ISSN	1556-6811
DOIs	https://doi.org/10.1128/CVI.00103-07
Publication status	Published - 2007

Keywords

B780-tropical-medicine
Protozoal diseases
Trypanosomiasis-African
Trypanosoma brucei gambiense
Stage determination
Laboratory techniques and procedures
Treatment failure
Relapses
Risk assessment
Neurologic disorders
Drug therapy
Suramin
Markers
Sensitivity
Specificity

Access to Document

10.1128/CVI.00103-07

http://lib.itg.be/pdf/itg/2007/2007cvim0732.pdf

Cite this

Lejon, V., Robays, J., N'Siesi, FX., Mumba, D., Hoogstoel, A., Bisser, S., Reiber, H., Boelaert, M., & Büscher, P. (2007). Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness. Clinical and Vaccine Immunology, 14(6), 732-737. https://doi.org/10.1128/CVI.00103-07

@article{248ce2bb81db4f9ab1540a0c0f74f25d,

title = "Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness",

keywords = "B780-tropical-medicine, Protozoal diseases, Trypanosomiasis-African, Trypanosoma brucei gambiense, Stage determination, Laboratory techniques and procedures, Treatment failure, Relapses, Risk assessment, Neurologic disorders, Drug therapy, Suramin, Markers, Sensitivity, Specificity",

author = "V Lejon and J Robays and FX N'Siesi and D Mumba and A Hoogstoel and S Bisser and H Reiber and M Boelaert and P B{\"u}scher",

note = "ITG-P1A; ITG-H2A; ITG-H8A; ITG-PLA; MULTI; PARAS; U-SEROL; HEALTH; U-EPID; JIF; DOI; PDF",

year = "2007",

doi = "10.1128/CVI.00103-07",

language = "English",

volume = "14",

pages = "732--737",

journal = "Clinical and Vaccine Immunology",

issn = "1556-6811",

publisher = "American Society for Microbiology",

number = "6",

}

Lejon, V, Robays, J, N'Siesi, FX, Mumba, D, Hoogstoel, A, Bisser, S, Reiber, H, Boelaert, M & Büscher, P 2007, 'Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness', Clinical and Vaccine Immunology, vol. 14, no. 6, pp. 732-737. https://doi.org/10.1128/CVI.00103-07

Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness. / Lejon, V; Robays, J; N'Siesi, FX et al.
In: Clinical and Vaccine Immunology, Vol. 14, No. 6, 2007, p. 732-737.

Research output: Contribution to journal › A1: Web of Science-article › peer-review

TY - JOUR

T1 - Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness

AU - Lejon, V

AU - Robays, J

AU - N'Siesi, FX

AU - Mumba, D

AU - Hoogstoel, A

AU - Bisser, S

AU - Reiber, H

AU - Boelaert, M

AU - Büscher, P

N1 - ITG-P1A; ITG-H2A; ITG-H8A; ITG-PLA; MULTI; PARAS; U-SEROL; HEALTH; U-EPID; JIF; DOI; PDF

PY - 2007

Y1 - 2007

KW - B780-tropical-medicine

KW - Protozoal diseases

KW - Trypanosomiasis-African

KW - Trypanosoma brucei gambiense

KW - Stage determination

KW - Laboratory techniques and procedures

KW - Treatment failure

KW - Relapses

KW - Risk assessment

KW - Neurologic disorders

KW - Drug therapy

KW - Suramin

KW - Markers

KW - Sensitivity

KW - Specificity

U2 - 10.1128/CVI.00103-07

DO - 10.1128/CVI.00103-07

M3 - A1: Web of Science-article

SN - 1556-6811

VL - 14

SP - 732

EP - 737

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

IS - 6

ER -